## Form PTO-1449 Substitute

U.S. Department of Commerce Patent and Trademark Office

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

AUG 1 5 2008

Application Number	10/585,017			
Filing Date	June 28, 2006			
Einst Named Income	Bara-Tana,			
First Named Inventor	Jacob			
Art Unit				
Examiner Name				
Attorney Docket No.	76581/JPW/CH			

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		4,634,795	01-06-1987	Bar-Tana
		4,689,344	08-25-1987	Bar-Tana
		4,711,896	12-08-1987	Bar-Tana, et al.
		5,641,810	06-24-1997	Pill, et al.
		6,284,903	09-04-2001	Bar-Tana
		6,303,653	10-16-2001	Bar-Tana
		5,225,182	07-06-1993	Sharma
		5,169,383	12-08-1992	Gyory, et al.
		5,167,616	12-01-1992	Haak, et al.
		4,959,217	09-25-1990	Sanders, et al.
		4,925,678	05-15-1990	Ranney
		4,487,603	12-11-1984	Harris
		4,486,194	12-04-1984	Ferrara
		4,447,233	05-08-1984	Mayfield
		4,447,224	05-08-1984	DeCant, Jr., et al.
		4,439,196	03-27-1984	Higuchi
		4,475,196	10-02-1984	La Zor
		6,303,653	10-16-2001	Bar-Tana

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>			
		WO - 98/30530	07-16-1998	Bar-Tana				
		WO - 99/00116	01-07-1999	Bar-Tana				

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Form P1	r <del>0-</del> 1	449 Substitute	U.S. Departme	nt of Commerce	Application Number	10/585,017	
			Patent and Tra	ademark Office	Filing Date	June 28, 2	
					First Named Inventor	Bara-Tana,	
INFORMATION DISCLOSURE STATEMENT				Jacob			
(Use several sheets if necessary)							
Examiner Name							
					Attorney Docket No.	76581/JPW/	СН
			NON PATENT	LITERATURE DOCUM	MENTS		
Examiner Initials	Cite No. <sup>1</sup>	(book, magazine, jou	rnal, serial, symposiu an	L LETTERS), title of the a m, catalog, etc.) date, page d/or country where publish	(s), volume-issue number ied.	(s), publisher, city	T <sup>2</sup>
		acetyl-CoA (	carboxylase nsulin-resis	(2002) "MEDIC and reduces pl stant JCR: LA-c	asma triacylg	lycerol	
		Bar-Tana, J., et al., (1989) "Synthesis and hypolipidemic and antidiabetogenic activities of beta, beta, beta'-tetrasubstituted, long-chain dioic acids" Journal of Medicinal Chemistry, 32(9):2072-2084					
		Bar-Tana, J., et al., (1988) "Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats" Journal of Lipid Research, 29(4):431-441					
		by beta beta omega-dicark	a'-tetrameth poxylic acid	(1985) "Inhibit nyl-substituted ds in the rat i 260(14):8404-84	, $C14-C22$ , aln vivo" The $\mathcal C$	pha,	
		tetramethyllllow-density	nexadecanedi lipoproteir	1994) "The effe loic acid (MEDI n metabolism in The Biochemical	CA 16) on pla rats: role c	sma very- of	
		of beta,beta (MEDICA 16)	a'-methyl-su is mediated	1988) "The hypoubstituted hexa d by a decrease ological Chemis	decanedioic a in apolipopr	cid cotein C-	
		predicted by	y the high H	al., (2001) " Fasting Insulin 27(2 Pt 1):117	-to-Glucose r		
		to insulin : Zucker rats	induced by t in vivo" An	(2003) "Adipose roglitazone an merican Journal polism, 284(4):	d MEDICA 16 i of Physiolog	.n obese	
EXAMINER SIGNATUR				DATE CONSIDERED			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

_							
Form P1	ΓO-1	449 Substitute	U.S. Departmen	nt of Commerce	Application Number	10/585,017	7
			Patent and Tra		Filing Date	June 28, 2	2006
					First Named Inventor	Bara-Tana,	
INFORM	MAT	ION DISCLOSU	JRE STATEME	NT	First Named Inventor	Jacob	
		sheets if necessar			Art Unit	<u> </u>	
					Examiner Name		
Attorney Docket No. 7				76581/JPW/	CH		
			NON PATENT I	LITERATURE DOCU	MENTS		
Examiner Initials	Cite No. <sup>1</sup>		rnal, serial, symposiur	LETTERS), title of the a n, catalog, etc.) date, page l/or country where publis	e(s), volume-issue numbe		T <sup>2</sup>
		treatment or		1992) "Effect phosphate pote 00-407			
		check index: insulin sens	: a simple, sitivity in	) "Quantitativaccurate methology" The Joolism, 85(7):2	od for assess: ournal of Clin	ing	
		assessment: fasting plas	insulin res	(1985) "Homedistance and be and insulin co -419	eta-cell funct		
		induced by h	oeta,beta'-m A 16) in obe	997) "Sensitiz ethyl-substitu se Zucker rats	ıted hexadecar	nedioic	
		beta beta'-r	methyl-subst	993) "Hypochol ituted hexaded " The Biochem:	canedioic acid	d (MEDICA	
		synthesis by alpha, omega	y beta beta' a-dicarboxyl	(1985) "Inhibitetramethyles ic acids in cum, 260(14):841	substituted, ( ultured rat		
		beta, beta'- hyperlipider <i>Thrombosis</i>	-tetramethyl mic JCR:LA-c	(1991) "Hypoli hexadecanedic orpulent rats' of Vascular B:	oic acid (MED ' Arterioscle	ICA 16) in rosis and	

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

Form P	I O-1	449 Substitute	U.S. Departmen	nt of Commerce	Application Number	10/383,01/	
			-	demark Office	Filing Date	June 28, 2	006
INFORMATION DISCLOSURE STATEMENT					First Named Inventor	Bara-Tana, Jacob	
				Art Unit			
(Use several sheets if necessary)					Examiner Name		
					Attorney Docket No.	76581/JPW/	CH
		<del></del>			<u> </u>	·	
			NON PATENT	LITERATURE DOCUM	MENTS		
Examiner Initials	Cite No. <sup>1</sup>		rnal, serial, symposiu	LETTERS), title of the a m, catalog, etc.) date, page d/or country where publisl	(s), volume-issue number		T <sup>2</sup>
		tetramethyl-	-substituted	) "Adipose red hexadecanedic of Obesity, 13(	oic acid (MEDI		
		hypoglycemic	-hypoinsuli hexadecaned	) "Hypolipidem nemic effects lioic acid in s	of beta, beta'	-methyl-	
				· · · · · · · · · · · · · · · · · · ·			
	2 - 7					1	
EXAMINEI SIGNATUR				DATE CONSIDERED			
					(00 B # + + + +		

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.